Penumbra, Inc. reported $1.50B of revenue over the trailing twelve months, +18% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.50B (to Q2 2026). Net income: $161M, trailing twelve months to Q2 2026. Free cash flow: $216M, trailing twelve months to Q2 2026. Operating margin: 12%, trailing twelve months to Q2 2026.

PENPenumbra, Inc.

Healthcare

$319.42+25% 1Y

$319.42

$225.5452 weeks$359.40

PEN as reported

Penumbra, Inc. reported $1.50B of revenue over the trailing twelve months, +18% on the year before. 10 reported series are charted on this page, each one as filed.

$1.50B

Revenue, trailing twelve months · to Q2 2026 · +18% against the twelve months before

Net income: $161M
Net income · +8.7% year on year · trailing twelve months to Q2 2026
Free cash flow: $216M
Free cash flow · +34% year on year · trailing twelve months to Q2 2026
Operating margin: 12%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PEN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.50B	+18%	Q2 2026
Net income	$161M	+8.7%	Q2 2026
EPS	$4.07	+8.0%	Q2 2026
Gross margin	68%	n/a	Q2 2026
Operating margin	12%	n/a	Q2 2026
Net margin	11%	n/a	Q2 2026
ROE	12%	n/a	Q2 2026
ROA	9.1%	n/a	Q2 2026
Free cash flow	$216M	+34%	Q2 2026
P/E	78.5	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.